Key Highlights

  • NASDAQ:AEHR shares are extending a multi-session rally tied to AI processor burn-in and test equipment demand.
  • A bullish Zacks note and a Zacks Rank #2 (Buy) rating have fueled the move.
  • Fiscal 2027 EPS estimates have risen sharply, to $0.70 from just $0.03 a year ago.
  • The stock is up roughly 327% year-to-date and over 111% in the past six months, trading at 17.5x forward price-to-sales versus the industry's 5.5x.

Zacks Note and Ratings Upgrade Drive Momentum

Aehr Test Systems (NASDAQ:AEHR) shares are surging, extending a remarkable multi-session rally driven by growing investor enthusiasm around the company's positioning in AI processor burn-in and test equipment. The latest leg of the move has been fueled by a bullish Zacks note highlighting AEHR's potential to convert AI chip testing Demand into durable long-term Revenue streams.

The note accompanies a Zacks Rank #2 (Buy) rating on the stock. Alongside the ratings action, fiscal 2027 EPS estimates for Aehr have risen sharply, climbing to $0.70 from just $0.03 a year earlier, a revision investors are citing as a key driver of renewed interest in the name.

A Standout Year-to-Date Performer

The stock has now returned roughly 327% year-to-date and gained over 111% in the past six months, vastly outpacing the broader semiconductor industry. That performance has been closely tied to expectations that Aehr can capture a growing share of AI-driven semiconductor test demand as chipmakers scale up production of AI processors requiring burn-in testing.

The rally has pushed Aehr's valuation to a steep premium relative to peers, with the stock trading at 17.5x forward price-to-sales versus the broader semiconductor industry's 5.5x. That gap reflects investor optimism about Aehr's growth trajectory, even as some Market Participants have raised questions about the sustainability of such a rich multiple.

What Investors Are Watching

Going forward, the key variables investors are tracking include whether AEHR's EPS estimate revisions continue and whether AI chip testing demand translates into the durable revenue streams the Zacks note describes, particularly given how far the stock's valuation has already moved ahead of the sector.

Q1. Why is Aehr Test Systems stock rallying?

A bullish Zacks note and a Zacks Rank #2 (Buy) rating, combined with sharply higher fiscal 2027 EPS estimates, have driven investor enthusiasm around Aehr's AI processor burn-in and test equipment positioning.

Q2. How much have fiscal 2027 EPS estimates for Aehr changed?

Estimates have risen to $0.70 from just $0.03 a year ago.

Q3. How does Aehr's valuation compare with the semiconductor industry?

Aehr trades at 17.5x forward price-to-sales versus the broader semiconductor industry's 5.5x.